180695-80-1

Usage

Uses

Used in Organic Chemistry:
Tert-butyl 4-azidopiperidine-1-carboxylate(SALTDATA: FREE) is used as a reagent for the preparation of various nitrogen-containing compounds. Its versatility in organic synthesis makes it a valuable building block for the creation of complex organic molecules.
Used in Click Chemistry:
In the field of click chemistry, tert-butyl 4-azidopiperidine-1-carboxylate(SALTDATA: FREE) is employed as a key component in copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions. This reaction is highly efficient and selective, allowing for the rapid and reliable formation of triazole linkages between molecular components. This makes it an ideal candidate for the construction of complex molecular architectures and the development of new materials and pharmaceuticals.
Used in Pharmaceutical Industry:
Tert-butyl 4-azidopiperidine-1-carboxylate(SALTDATA: FREE) is used as a synthetic intermediate for the development of pharmaceutical compounds. Its ability to participate in click chemistry reactions enables the rapid assembly of bioactive molecules with potential therapeutic applications.
Used in Material Science:
In material science, tert-butyl 4-azidopiperidine-1-carboxylate(SALTDATA: FREE) is utilized in the synthesis of novel materials with unique properties. Its involvement in click chemistry reactions allows for the creation of functional materials with tailored characteristics, such as self-healing properties, stimuli-responsive behavior, and improved mechanical strength.
Used in Bioconjugation:
Tert-butyl 4-azidopiperidine-1-carboxylate(SALTDATA: FREE) is used as a bioconjugation agent to attach biologically relevant molecules, such as peptides, proteins, and nucleic acids, to various surfaces or other molecular entities. The high selectivity and efficiency of click chemistry reactions facilitate the precise and stable attachment of these biomolecules, enabling their use in biosensors, drug delivery systems, and other bioanalytical applications.

Upstream product

• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 90633-18-4 4-bromo-1H-piperidine 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 180695-79-8 tert-butyl 4-bromo-1-piperidinecarboxylate 

Downstream Products

• 180695-85-6 tert-butyl 4-(4-phenyl-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 1233955-69-5 tert-butyl 4-[(methylcarbamoyl)amino]piperidine-1-carboxylate 
• 220394-97-8 4-(benzyloxycarbonylamino)-1-(tert-butoxycarbonyl)piperidine 
• 847039-05-8 4-(((benzyloxy)carbonyl)(methyl)amino)piperidine-1-carboxylic acid tert-butyl ester 
• 220394-98-9 4-(benzyloxycarbonyl-propyl-amino)-piperidine-1-carboxylic acid tert-butyl ester 
• 235420-64-1 4-(allyl-benzyloxycarbonyl-amino)-piperidine-1-carboxylic acid tert-butyl ester 
• 139062-98-9 piperidin-4-ylmethyl-carbamic acid benzyl ester hydrochloride 

Relevant academic research and scientific papers

Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor

A potent inhibitor of the JmjC histone lysine demethylase KDM2A (compound 35, pIC50 7.2) with excellent selectivity over representatives from other KDM subfamilies has been developed; the discovery that a triazolopyridine compound binds to the active site of JmjC KDMs was followed by optimisation of the triazole substituent for KDM2A inhibition and selectivity. This journal is

Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapachol-based compounds

Lapachol is an abundant prenyl naphthoquinone occurring in Brazilian Bignoniaceae that was clinically used, in former times, as an antimalarial drug, despite its moderate effect. Aiming to search for potentially better antimalarials, a series of 1,2,3-triazole derivatives was synthesized by chemical modification of lapachol. Alkylation of the hydroxyl group gave its propargyl ether which, via copper-catalyzed cycloaddition (CuAAC) click chemistry with different organic azides, afforded 17 naphthoquinonolyl triazole derivatives. All the synthetic compounds were evaluated for their in vitro activity against chloroquine resistant Plasmodium falciparum (W2) and for cytotoxicity to HepG2 cells. Compounds containing the naphthoquinolyl triazole moieties showed higher antimalarial activity than lapachol (IC50 123.5 μM) and selectivity index (SI) values in the range of 4.5–197.7. Molecular docking simulations of lapachol, atovaquone and all the newly synthesized compounds were carried out for interactions with PfDHODH, a mitochondrial enzyme of the parasite respiratory chain that is essential for de novo pyrimidine biosynthesis. Docking of the naphthoquinonolyl triazole derivatives to PfDHODH yielded scores between ?9.375 and ?14.55 units, compared to ?9.137 for lapachol and ?12.95 for atovaquone and disclosed the derivative 17 as a lead compound. Therefore, the study results show the enhancement of DHODH binding affinity correlated with improvement of SI values and in vitro activities of the lapachol derivatives.

Novel histone deacetylase inhibitors bearing a 4-piperidin-4-yl-triazole scaffold as antitumor agents

Histone deacetylases have proven to be promising targets for the development of anticancer drugs. In this work, we reported the design and synthesis of a series of 20 novel hydroxamic acid-based histone deacetylase inhibitors with 4-piperidin-4-yl-triazole as the core structure. Five newly obtained compounds displayed excellent HDAC6 inhibitory activities. Among them, compounds WY-12 and WY-15 also exhibited excellent antiproliferative activities against six human tumor cell lines. WY-15 could increase the level of acetylated histone H3 in a dose-dependent manner. Furthermore, WY-15 remarkably induced cell cycle arrest of Sy5y cancer cells in G0/G1 phase. Finally, the high potency of compound WY-15 toward HDAC6 was rationalized by molecular docking study.

INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER

The present invention relates to indole derivatives of formula (I') as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.

Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach

Akt is a protein kinase that has been implicated in the progression of cancerous tumours. A number of covalent allosteric Akt inhibitors are known, and based on these scaffolds, a small library of novel potential covalent allosteric imidazopyridine-based inhibitors was designed. The envisaged compounds were synthesised, with click chemistry enabling a modular approach to a number of the target compounds. The binding modes, potencies and antiproliferative activities of these synthesised compounds were explored, thereby furthering the structure activity relationship knowledge of this class of Akt inhibitors. Three novel covalent inhibitors were identified, exhibiting moderate activity against Akt1 and various cancer cell lines, potentially paving the way for future covalent allosteric inhibitors with improved properties.

TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS

Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

1, 2, 4-OXADIAZOLE DERIVATIVES AND USES THEREOF

The disclosure provides 1, 2, 4-oxadiazole derivatives useful for stemming bleeding and for treating cancer.

1, 3, 4-OXADIAZOLE DERIVATIVES AND USES THEREOF

The disclosure provides 1, 3, 4-oxadiazole derivatives useful for stemming bleeding and for treating cancer.

Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor

As regulators of transcription, epigenetic proteins that interpret post-translational modifications to N-terminal histone tails are essential for maintaining cellular homeostasis. When dysregulated, "reader" proteins become drivers of disease. In the case of bromodomains, which recognize N-?-acetylated lysine, selective inhibition of individual bromodomain-and-extra-terminal (BET)-family bromodomains has proven challenging. We describe the >55-fold N-terminal-BET bromodomain selectivity of 1,4,5-trisubstituted-imidazole dual kinase-bromodomain inhibitors. Selectivity for the BRD4 N-terminal bromodomain (BRD4(1)) over its second bromodomain (BRD4(2)) arises from the displacement of ordered waters and the conformational flexibility of lysine-141 in BRD4(1). Cellular efficacy was demonstrated via reduction of c-Myc expression, inhibition of NF-κB signaling, and suppression of IL-8 production through potential synergistic inhibition of BRD4(1) and p38α. These dual inhibitors provide a new scaffold for domain-selective inhibition of BRD4, the aberrant function of which plays a key role in cancer and inflammatory signaling.

JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF

Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. ( 00A)